Answers are grounded in this paper and cite their sources.
The FDA approved giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer based on the results of the phase III evERA trial. In addition, the agency authorized the FoundationOne Liquid CDx assay for assessing ESR1 status to determine who would benefit from this treatment regimen.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: